Skip to main content

Table 4 Cox model analysis for 66 ESCC patients with locoregional recurrence after matching

From: Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis

Variable n Univariate Multivariate
HR 95%CI P HR 95%CI P
Age (years)
  < 65/≥65 42/24 0.736 0.407–1.330 0.310    
KPS
 70–80/>80 27/39 0.843 0.491–1.447 0.535    
Gender
 Male/Female 48/18 0.942 0.530–1.674 0.838    
Smoking
 Yes/No 23/43 1.486 0.857–2.577 0.159    
Alcohol consumption
 Yes/No 10/56 1.083 0.526–2.233 0.828    
Primary tumor location
 Upper/Middle and lower thoracic 27/39 1.265 0.733–2.183 0.398    
Clinical stage
 I + II/III 20/46 1.021 0.561–1.858 0.946 1.541 0.814–2.916 0.184
Surgery in the initial treatment
 Yes/No 6/60 2.258 0.942–5.414 0.068    
Chemotherapy in the initial treatment
 Yes/No 33/33 1.005 0.585–1.729 0.984    
Recurrence-free interval (months)
 ≤12/> 12 29/37 0.739 0.433–1.262 0.268    
Pattern of recurrence
 LN/PF 9/57 0.277 0.108–0.714 0.008 0.319 0.117–0.869 0.025
Re-RT after recurrence
 Yes/No 33/33 0.299 0.167–0.535 < 0.001 0.375 0.201–0.701 0.002
Chemotherapy after recurrence
 Yes/No 20/46 0.817 0.456–1.463 0.497    
Chemotherapy for both course treatment
 Yes/No 10/56 0.621 0.291–1.323 0.217 0.710 0.323–1.562 0.395
  1. Abbreviations: HR Hazard ratio, 95%CI 95% confidence interval, Re-RT Re-irradiation, LN Regional lymph node recurrence alone, PF Primary failure with/without regional lymph node recurrence, KPS Karnofsky performance status